BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) – Analysts at Leerink Partnrs dropped their Q3 2025 earnings estimates for BridgeBio Pharma in a report issued on Monday, June 30th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($0.79) per share for the quarter, down from their prior forecast of ($0.78). The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.67) per share. Leerink Partnrs also issued estimates for BridgeBio Pharma’s Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.87) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at $0.66 EPS, FY2028 earnings at $3.50 EPS and FY2029 earnings at $5.52 EPS.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.12. The company had revenue of $36.74 million for the quarter, compared to the consensus estimate of $57.14 million. The firm’s revenue for the quarter was down 44.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) EPS.
Check Out Our Latest Stock Report on BridgeBio Pharma
BridgeBio Pharma Stock Up 2.0%
Shares of BridgeBio Pharma stock opened at $43.71 on Thursday. The company has a market cap of $8.30 billion, a price-to-earnings ratio of -12.38 and a beta of 1.15. The company’s 50 day moving average is $37.93 and its 200 day moving average is $34.63. BridgeBio Pharma has a twelve month low of $21.72 and a twelve month high of $45.48.
Insider Activity at BridgeBio Pharma
In related news, CEO Neil Kumar sold 75,000 shares of the firm’s stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $34.11, for a total transaction of $2,558,250.00. Following the completion of the transaction, the chief executive officer directly owned 4,873,447 shares of the company’s stock, valued at approximately $166,233,277.17. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Frank Mccormick sold 100,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $44.23, for a total transaction of $4,423,000.00. Following the completion of the transaction, the director directly owned 879,979 shares of the company’s stock, valued at $38,921,471.17. The trade was a 10.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,936,181 shares of company stock valued at $375,878,164 in the last ninety days. Corporate insiders own 18.20% of the company’s stock.
Institutional Trading of BridgeBio Pharma
A number of large investors have recently made changes to their positions in BBIO. Steward Partners Investment Advisory LLC increased its holdings in shares of BridgeBio Pharma by 85.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of BridgeBio Pharma by 71.0% in the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company’s stock worth $32,000 after buying an additional 382 shares during the last quarter. Jones Financial Companies Lllp bought a new stake in shares of BridgeBio Pharma in the 1st quarter worth about $35,000. Itau Unibanco Holding S.A. bought a new stake in shares of BridgeBio Pharma in the 4th quarter worth about $41,000. Finally, Sterling Capital Management LLC increased its holdings in shares of BridgeBio Pharma by 554.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock worth $49,000 after buying an additional 1,514 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors.
About BridgeBio Pharma
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Featured Articles
- Five stocks we like better than BridgeBio Pharma
- Stock Sentiment Analysis: How it Works
- The Apple Comeback Will Be Better Than the Setback
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- How a Government Loan Changes the Game for Plug Power
- What is the Hang Seng index?
- Qualcomm’s Hold Rating Misses Strong Growth Story
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.